Share ownership Altimmune, Inc.

ALT

US02155H2004

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2025-07-11 EDT			5-day change	1st Jan Change
4.140 ^USD	-5.91%		-13.03%	-42.58%

07-09	Altimmune, Inc. Announces Initiation of Restore Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease	CI
06-30	Altimmune, Inc.(NasdaqGM:ALT) dropped from Russell 3000E Value Index	CI

Share class: Altimmune, Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	71,124,625	70,559,934 ( 99.21 %)	0	99.21 %

Major shareholders: Altimmune, Inc.

Name	Equities	%	Valuation
BlackRock Advisors LLC 8.207 %	5,837,087	8.207 %	23 M $
Vanguard Fiduciary Trust Co. 6.197 %	4,407,462	6.197 %	17 M $
STATE STREET CORPORATION 4.768 %	3,391,571	4.768 %	13 M $
Tang Capital Management LLC 3.866 %	2,750,000	3.866 %	11 M $
Geode Capital Management LLC 2.398 %	1,705,885	2.398 %	7 M $
Ameriprise Financial Services LLC 2.03 %	1,443,932	2.03 %	6 M $
Marshall Wace LLP 1.643 %	1,168,338	1.643 %	5 M $
Two Sigma Investments LP 1.614 %	1,147,816	1.614 %	4 M $
Knoll Capital Management LP 1.577 %	1,121,524	1.577 %	4 M $
Millennium Management LLC 1.562 %	1,111,299	1.562 %	4 M $
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	44.5%
State Street Corp.	4.77%
Other	4.4%
Individuals	0.98%
Schweizerische Nationalbank	0.2%
Silvercrest Asset Management Group, Inc.	0.15%
Corebridge Financial, Inc.	0.05%
Baader Bank AG	0.05%
Manulife Financial Corp.	0.04%
Cullen/Frost Bankers, Inc.	0.01%
Unknown	44.85%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	46.07%
United Kingdom	6.13%
Individuals	0.98%
Australia	0.67%
Switzerland	0.49%
Canada	0.38%
Ireland	0.18%
Luxembourg	0.06%
Spain	0.05%
Germany	0.05%
China	0.04%
Norway	0.02%
Japan	0.01%
Israel	0.01%

Based on 1000 largest holdings

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. The Company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. It is also developing HepTcell, an immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus (HBV). The Company has completed the enrollment in its Phase II clinical trial of HepTcell. Its product candidates are based on its proprietary platform technologies, such as EuPort-based Peptide Technology and Synthetic Peptide Technology-Densigen. The Companyâs wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.

Employees

Sector

Biotechnology & Medical Research

Calendar

08-06 - Q2 2025 Earnings Release (Projected)

More about the company